Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 21, 2024

BUY
$4.78 - $7.22 $3,025 - $4,570
633 Added 97.84%
1,280 $6,000
Q3 2023

Oct 30, 2023

BUY
$4.78 - $7.22 $3,025 - $4,570
633 Added 97.84%
1,280 $6,000
Q2 2023

May 21, 2024

SELL
$4.53 - $8.4 $40 - $75
-9 Reduced 1.37%
647 $4,000
Q2 2023

Jul 27, 2023

SELL
$4.53 - $8.4 $40 - $75
-9 Reduced 1.37%
647 $4,000
Q1 2023

May 21, 2024

BUY
$5.95 - $8.21 $975 - $1,346
164 Added 33.33%
656 $5,000
Q1 2023

Apr 27, 2023

BUY
$5.95 - $8.21 $975 - $1,346
164 Added 33.33%
656 $5,000
Q4 2022

May 21, 2024

BUY
$6.71 - $9.72 $3,301 - $4,782
492 New
492 $3,000
Q4 2022

Jan 31, 2023

BUY
$6.71 - $9.72 $369 - $534
55 Added 12.59%
492 $4,000
Q3 2022

Oct 21, 2022

BUY
$7.17 - $12.16 $3,133 - $5,313
437 New
437 $4,000

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $397M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.